Glimepirid 1a Pharma (Glimepiride)

Glimepirid 1a Pharma is indicated for the management of hyperglycemia in adults with type 2 diabetes mellitus, typically as an adjunct to diet and exercise.

• Improves fasting and post‑prandial blood glucose levels.
• Can be combined with metformin or other oral antidiabetic agents when monotherapy is insufficient.
• May be used in patients who have not achieved glycemic control with lifestyle measures alone.
• Suitable for patients with preserved pancreatic beta‑cell function.
• Often prescribed when a second‑generation sulfonylurea is preferred for its potency and duration of action.

Side effects reported with glimepiride may vary in frequency and severity.

Common

• Mild to moderate hypoglycemia, characterized by shakiness, sweating, or hunger, particularly when meals are delayed or skipped.
• Gradual weight gain, often modest, associated with improved glycemic control.
• Nausea, occasional abdominal discomfort, or dyspepsia that may lessen over time.
• Transient headache or dizziness, usually not requiring medical intervention.

Serious

• Severe hypoglycemia with symptoms such as confusion, loss of consciousness, or seizures, requiring immediate treatment.
• Allergic reactions ranging from skin rash and pruritus to angioedema or urticaria.
• Hematologic changes including leukopenia, neutropenia, or thrombocytopenia that may be detected on routine blood tests.
• Hepatic injury presenting as elevated liver enzymes, jaundice, or hepatitis‑like symptoms.

When prescribing Glimepirid 1a Pharma, clinicians consider several precautionary factors to ensure safe use.

• Assess renal and hepatic function before initiation and periodically during therapy.
• Use the lowest effective dose, especially in elderly patients or those with reduced beta‑cell reserve.
• Counsel patients on recognizing and managing hypoglycemia, including the importance of regular meals.
• Avoid use in patients with known sulfonylurea hypersensitivity.
• Monitor blood glucose closely during dose adjustments or when adding interacting medications.
• Consider pregnancy and lactation status; the safety profile is not well established.

Glimepirid 1a Pharma may interact with other drugs that affect blood glucose or sulfonylurea metabolism.

Avoid

• Concurrent use with other sulfonylureas or meglitinides, which can increase risk of severe hypoglycemia.
• Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that may raise glimepiride plasma concentrations.

Use with caution

• Beta‑blockers, which can mask hypoglycemia symptoms.
• Thiazide diuretics, which may potentiate hypoglycemic effect.
• Anticoagulants such as warfarin, as glimepiride may alter INR values.
• Alcohol intake, which can enhance hypoglycemic episodes.